Radnor Capital Management LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 2.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 33,701 shares of the company’s stock after purchasing an additional 930 shares during the quarter. Johnson & Johnson comprises about 1.7% of Radnor Capital Management LLC’s portfolio, making the stock its 8th largest holding. Radnor Capital Management LLC’s holdings in Johnson & Johnson were worth $4,731,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently made changes to their positions in the company. Sofos Investments Inc. raised its stake in shares of Johnson & Johnson by 172.0% in the first quarter. Sofos Investments Inc. now owns 1,148 shares of the company’s stock worth $33,000 after purchasing an additional 726 shares during the last quarter. Altshuler Shaham Ltd acquired a new position in Johnson & Johnson in the 1st quarter worth approximately $35,000. Lake Point Wealth Management raised its position in Johnson & Johnson by 144.4% during the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after buying an additional 169 shares during the last quarter. Lion Street Advisors LLC acquired a new stake in Johnson & Johnson during the 1st quarter valued at approximately $45,000. Finally, SeaBridge Investment Advisors LLC lifted its stake in Johnson & Johnson by 160.0% during the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares during the period. 68.44% of the stock is owned by hedge funds and other institutional investors.
In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the transaction, the executive vice president now owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.27% of the stock is currently owned by insiders.
Johnson & Johnson stock opened at $145.76 on Friday. The stock has a market capitalization of $383.76 billion, a P/E ratio of 18.29, a P/E/G ratio of 3.23 and a beta of 0.69. The company’s fifty day moving average price is $144.04 and its 200 day moving average price is $144.14. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.05 and a current ratio of 1.25. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.17. The business had revenue of $18.34 billion for the quarter, compared to the consensus estimate of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The company’s revenue was down 10.8% compared to the same quarter last year. During the same period last year, the firm posted $2.58 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 7.85 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.01 dividend. This represents a $4.04 annualized dividend and a yield of 2.77%. The ex-dividend date of this dividend is Monday, August 24th. Johnson & Johnson’s payout ratio is 46.54%.
Several research analysts recently issued reports on JNJ shares. Citigroup raised their target price on shares of Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Cantor Fitzgerald reiterated a “buy” rating and set a $168.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, April 28th. SVB Leerink restated an “outperform” rating on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price target for the company. in a research report on Tuesday, July 7th. Finally, Credit Suisse Group restated a “buy” rating and issued a $161.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, April 28th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $163.38.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What is a management fee?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.